According to Consumer Reports, "Those taking sleeping pills have high risks and limited benefits. Looking for help for Sonata Withdrawal Tried to Quit Sonata? We take a natural, holistic approach to Sonata Withdrawal since promoting sleep is critical. Our advanced nutraceuticals help soon the nervous system and combine with a slow taper from Sonata, then it is possible to escape Sonata dependence. Let our nonprofit help you come off Sonata. Zaleplon is sold under the brand name Sonata, a sedative-hypnituc that is addictive. Contact Us Today.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
" After almost 38 years on psychoactive drugs, I am now totally free of them! With Point of Return's Help!" - Holly (Sleeping Pill Withdrawal Success Story)
Our Sonata weaning program is a slow taper that allows you to come off Sonata under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Sonata until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Sonata withdrawal and support well-being.*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Sonata Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Sonata alone, work with our Prescription Drug Experts.
Imagine being Free of Sonata Dependency
- Proven Program completed In-Home with Expert Guidance
- Slowly Wean off Sonata
- All-Natural Nutraceuticals to help Ease Sonata Withdrawal
- Professional information on interactions
- Free Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
SLEEPING PILL WITHDRAWAL SUCCESS STORIES
I am proud of my accomplishment, completely and entirely due to you, your team and your program. More...
Dene H. (Ambien Withdrawal Success Story)
I tapered successfully off of Ambien and today I am entirely drug-free and I fall asleep every night! More...
Bianca (Ambien Withdrawal Success Story)
God put you on my life's Master Plan as His agent to restore and change my life and arrive at my Point of Return. Indeed I have arrived! I am truly grateful! More...
Nomusa (Ambien Withdrawal Success Story)
EXPERIENCE and TEAMWORK
using a Natural Approach
Sonata History and Information
Sonata is a hypnotic that is prescribed for the treatment of insomnia.
Sonata should only be used short term due to the risk of tolerance, drug dependence, rebound insomnia and central nervous system related adverse effects. Once tolerance to the sleeping pill has occurred it is recommended to do a gradual dose reduction to minimize symptoms that resemble benzodiazepine withdrawal.
Sonata is a hypnotic that is prescribed for the treatment of insomnia. Although Sonata binds to the same family of receptors as benzodiazepines, it is considered a class of sedative drugs called cyclopyrrones, which are called nonbenzodiazepines.
Sleeping pills are classified as sedative hypnotics and work on receptors in the brain to slow down the nervous system to induce and maintain sleep. The newer medications do have a different chemical structure from a benzodiazepine, but they act more specifically in the same area of the brain on the Gamma-aminobutyric acid receptors (GABA). Therefore the hypnotic effects are similar to benzodiazepines even though sleeping pills are molecularly distinct. The term non-benzodiazepines was given to these new classes of sleeping pills, making many believe they will not experience dependence. But the warnings from the manufactures of zolpidem (Ambien) state, “Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation and hallucinations may occur.” Continuous use is not recommended for more than 7--14 days. Similar warnings appear for all sleeping pills.
A trial performed by Dr. J.F. Pagel, a sleep physician at the University of Colorado Medical School, indicated that bizarre actions being committed while on sleeping pills are very prevalent. There have been 4 cases of murder in which the defendant was found not guilty due to a blackout and subsequent amnesia while on sleeping pills.
Sonata Withdrawal Symptoms, Side Effects, Adverse Reactions
SONATA WITHDRAWAL SYMPTOMS MAY INCLUDE:
abdominal pains, aching, agoraphobia, anxiety, blurred vision, body vibrations, changes in perception, diarrhea, distended abdomen, feeling of unreality, flu-like symptoms, flatulence, food cravings, hair loss, heart palpitations, heavy
limbs, increased allergies, increased sense of smell, insomnia, lethargy, loss of balance, metallic taste, muscle spasms, nightmares, panic attacks, paranoia, persistent & unpleasant memories, severe headaches, shaking, short term
memory loss, sore mouth and tongue, sound & light sensitivity, speech difficulties, sweating, suicidal thoughts, tinnitus, unusually sensitive, fear.
SONATA SIDE EFFECTS MAY INCLUDE:
drowsiness, dizziness, lightheadedness, difficulty with coordination, memory loss or amnesia, tolerance, dependence, changes in behavior and thinking; such as more outgoing or aggressive behavior than normal, confusion, strange behavior, agitation, hallucinations, worsening of depression, suicidal thoughts
SONATA ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: visual impairment, bronchospasm, GI obstruction, peptic ulcer, hearing loss, retinal detachment, ocular hemorrhage, corneal erosion, pleural effusion, apnea, cyanosis, ventricular tachycardia, bradycardia, pulmonary embolism, pericardial effusion, anaphylactoid reactions, angioedema, seizures
Moderate: amnesia, hyperesthesia, hyperacusis, gastritis, melena, glossitis, stomatitis, oral ulceration, esophagitis, colitis, edema, euphoria, hypotonia, nystagmus, hallucinations, ataxia, hypertonia, confusion, neuropathic pain, photophobia, atopic dermatitis, contact dermatitis, dyspenea, myashenia, hematura, nephrolithiasis, impotence, urinary incontinence, vaginitis, cystitis, dysuria, hypercholesterolemia, gout, peripheral edema, bundle-branch block, angina, peripheral vasodilation, hypotension, palpitations, hypertension, sinus tachycardia, lymphadenopathy, anemia, cholelithiasis, teeth grinding (bruxism), dysphagia, elevated hepatic enzymes, dysarthria, myoclonia, dystonic reaction, trismus, hyperreflexia, hostility, blepharitis, cataracts, psoriasis, osteoporosis, vaginal bleeding, urinary retention, proteinuria, hypoglycemia, hyperglycemia, hyperuricemia, hyperbilirubinemia, orthostatic hypotension, diabetes mellitus, goiter, hypothyroidism, eosinophilia, lymphocytosis, constipation, depression, conjunctivitis, chest pain (unspecified), impaired cognition, memory impairment,
complex sleep-related behaviors, respiratory depression, physiological dependence
Mild: headache, dizziness, nausea, asthenia, abdominal pain, drowsiness, ocular pain, dysmenorrhea, paresthesias, anorexia, malaise, tremor, parosmia, gingivitis, tongue discoloration, flatulence, eructation, appetite stimulation, vertigo, libido decrease, emotional lability, agitation, hyperkinesis, xerophthalmia, tinnitus, diplopia, otalgia, photosensitivity, acne vulgaris, urticaria, maculopapular rash, xerosis, hyperhidrosis, alopecia, epistaxis, laryngitis, arthropathy, menorrhagia, increased urinary frequency, mastalgia, urinary urgency, weight gain, syncope, ecchymosis, cheilitis, hypersalivation, hyporeflexia, ptosis, psychomotor impairment, somnambulism, skin discoloration, hiccups, hyperventilation, menstrual irregularity, leukorrhea, weight loss, lactose intolerance, leukocytosis, purpura, dyspepsia, xerostomia, back pain, fever, anxiety, dysgeusia, rash, pruritus, myalgia, arthralgia, nightmares, abnormal dreams, insomnia
SONATA BOXED WARNINGS: per PDR
Coadministration with other CNS depressants, complex sleep-related behaviors, driving or operating machinery, drug-induced complex sleep-related behaviors, ethanol ingestion
Sedative-hypnotics can cause complex sleep-related behaviors such as phone calls, sexual activity, preparing and eating food, or sleep-driving while not fully awake and in some cases having no memory of the event. These behaviors appear to be more frequent with nonbenzodiazepine benzodiazepine-receptor agonists (NBRAs), such as zaleplon, than other sedative-hypnotics. Although rare, serious injuries or death have occurred; therefore, zaleplon and other NBRAs are contraindicated in patients with a history of drug-induced complex sleep-related behaviors. Patients should be informed of the risks before receiving any medication from this class, including instructions to discontinue the medication if they experience a sleep-related episode and to contact their healthcare provider immediately. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of NBRAs to the FDA MedWatch Safety Information and Adverse Event Reporting Program. Because zaleplon has a rapid onset of action and causes CNS depressant effects, the drug should only be administered immediately prior to going to bed or after the patient has gone to bed and has experienced difficulty falling asleep. Patients should be cautioned against driving or operating machinery or performing other tasks that require mental alertness or motor coordination after taking their dose. The risk of next-day psychomotor impairment, including impaired driving, is increased if zaleplon is taken with less than a full night of sleep remaining (7 to 8 hours); if the dose taken is greater than the recommended dose; or during coadministration with other CNS depressants, alcohol, or drugs that increase zaleplon drug concentrations. Because zaleplon can cause drowsiness and a decreased level of consciousness, there is a higher risk of falls, particularly in the elderly, with the potential for subsequent severe injuries. As with all sedative/hypnotics, patients should be warned that taking zaleplon while still up and about may result in short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness. Dosage adjustment of zaleplon may be necessary during coadministration with other CNS depressants because of the potential for additive effects. Do not use zaleplon with other sedative-hypnotic agents, and ethanol ingestion should be avoided during use. Zaleplon potentiates alcohol-induced impairment and there is an increased risk of complex sleep-related behaviors during concurrent use of zaleplon and alcohol or other CNS depressants. Amnesia and other neuropsychiatric symptoms may occur unpredictably.
Sonata References and FDA Information
According to the FDA:
You may have withdrawal symptoms when you stop taking SONATA. Withdrawal symptoms include unpleasant feelings, stomach and muscle cramps, vomiting, sweating, shakiness, and rarely seizures. You may also have more trouble sleeping the first few nights after Sonata is stopped. The problem usually goes away on its own after 1 or 2 nights.
Withdrawal-Emergent Anxiety and Insomnia
During nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of hypnotics may develop. If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (ie, in relationship to the receptor site) may occur at some point in the interval between each night's use. This sequence of events is believed to be responsible for two clinical findings reported to occur after several weeks of nightly use of other rapidly eliminated hypnotics: increased wakefulness during the last quarter of the night and the appearance of increased signs of daytime anxiety.
Zaleplon has a short half-life and no active metabolites. At the primary efficacy endpoint (nights 29 and 30) in a 35-night sleep laboratory study, polysomnographic recordings showed that wakefulness was not significantly longer with Sonata than with placebo during the last quarter of the night. No increase in the signs of daytime anxiety was observed in clinical trials with Sonata. In two sleep laboratory studies involving 14- and 28-nightly doses of Sonata (5 mg and 10 mg in one study and 10 mg and 20 mg in the second) and structured assessments of daytime anxiety, no increases in daytime anxiety were detected. Similarly, in a pooled analysis (all the parallel- group, placebo-controlled studies) of spontaneously reported daytime anxiety, no difference was observed between Sonata and placebo.
Rebound insomnia, defined as a dose-dependent temporary worsening in sleep parameters (latency, total sleep time, and number of awakenings) compared to baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics. Rebound insomnia following discontinuation of Sonata relative to baseline was examined at both nights 1 and 2 following discontinuation in three sleep laboratory studies (14, 28, and 35 nights) and five outpatient studies utilizing patient diaries (14 and 28 nights). Overall, the data suggest that rebound insomnia may be dose dependent. At 20 mg, there appeared to be both objective (polysomnographic) and subjective (diary) evidence of rebound insomnia on the first night after discontinuation of treatment with Sonata. At 5 mg and 10 mg, there was no objective and minimal subjective evidence of rebound insomnia on the first night after discontinuation of treatment with Sonata. At all doses, the rebound effect appeared to resolve by the second night following withdrawal. In the 35-night study, there was a worsening in sleep on the first night off for both the 10-mg and 20-mg groups compared to placebo, but not to baseline. This discontinuation-emergent effect was mild, had the characteristics of the return of the symptoms of chronic insomnia, and appeared to resolve by the second night after zaleplon discontinuation.
Other Withdrawal-Emergent Phenomena
The potential for other withdrawal phenomena was also assessed in 14- to 28-night studies, including both the sleep laboratory studies and the outpatient studies, and in open-label studies of 6- and 12-month durations. The Benzodiazepine Withdrawal Symptom Questionnaire was used in several of these studies, both at baseline and then during days 1 and 2 following discontinuation. Withdrawal was operationally defined as the emergence of 3 or more new symptoms after discontinuation. Sonata was not distinguishable from placebo at doses of 5 mg, 10 mg, or 20 mg on this measure, nor was Sonata distinguishable from placebo on spontaneously reported withdrawal-emergent adverse events. There were no instances of withdrawal delirium, withdrawal associated hallucinations, or any other manifestations of severe sedative/hypnotic withdrawal.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More..